Drug intelligence / Profile preview

fimasartan + indapamide

Development stage
Phase 3
Lead developer
Boryung
Modality
Small Molecules
Administration
Oral
01

Overview

Fimasartan + indapamide is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure (hypertension). Fimasartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the type 1 angiotensin II receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood volume. This results in lower blood pressure and protective effects against cardiovascular events such as stroke and heart failure[2][6]. Indapamide is a thiazide-like diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal tubules of the kidney, thereby reducing fluid retention and lowering blood pressure[1][3]. The combination targets different mechanisms involved in hypertension for additive or synergistic antihypertensive effects.

Brand names
Kanarb V
Other names
BR1015 combination therapyBR-1015 combination therapyBR 1015 combination therapy
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on fimasartan + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fimasartan + indapamide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call